A new study shows for the very first time that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol from the bloodstream, may be inhibited by a third protein, annexin A2.
A new study shows for the very first time that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol from the bloodstream, may be inhibited by a third protein, annexin A2.